Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. - Wikidata - awgldk - TriplyDB

Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.

Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.

http://www.wikidata.org/entity/Q37933439

about

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Oncolysis by paramyxoviruses: preclinical and clinical studies.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Oncolytic virotherapy for gliomas: steps toward the future.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Fusogenic Viruses in Oncolytic Immunotherapy

P2860

Q35596563-A3D706B6-3B48-41AC-B8E7-C6693C1558DA Q35861933-580D54E3-E57C-45A3-8614-9956F83A0CBB Q36582819-540075AA-A1A2-441B-8CAE-8F3D0F285485 Q38025696-619B1BB1-1CA0-4DE0-87E8-D04857815B79 Q38209337-4163BEB6-792E-4618-8A0C-4E2C6899B1B2 Q43436260-380EB7F7-3BCF-49F0-A66E-BCCF885E191F Q54378300-4A9C7EA2-FC0F-4D77-BE6A-4DB7FCBA954E Q56971929-8A9E5DB8-8B25-4134-AC0A-46950F7B7F33

P2860

Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.

http://www.wikidata.org/entity/Q37933439

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Replicating viral vectors for ...... ze with host immune responses.

@en

Replicating viral vectors for ...... ze with host immune responses.

@nl

type

label

Replicating viral vectors for ...... ze with host immune responses.

@en

Replicating viral vectors for ...... ze with host immune responses.

@nl

prefLabel

Replicating viral vectors for ...... ze with host immune responses.

@en

Replicating viral vectors for ...... ze with host immune responses.

@nl

P1433

Q37933439-38EBE9F1-FE84-47EB-BCAD-D0C0569D084F

P1476

Q37933439-7B35A7EE-F976-4212-A3D4-4B57A79FCA6A

P2093

Q37933439-187F39B4-57FE-48C9-9B20-C780B23F7307

Q37933439-B18F14D2-A51E-46CB-834E-F3BB3700ACC9

P2860

Q37933439-04F0563C-3C40-4564-B523-52141E8D9343

Q37933439-09E6FD85-BEE8-4FDB-8289-A402A71E4BB9

Q37933439-0AD5A1B8-47BA-41F2-BF79-8D4950E90FD6

Q37933439-0B548385-3F8D-439A-9B16-6D3AB0FE8B54

Q37933439-0CF866E5-7655-4CDE-A060-449BD3FDDA65

Q37933439-0D81AB9F-314D-4B2B-84D0-FD91254FC6D4

Q37933439-0FF8C261-86BC-49AB-817F-1F73F6E7EC37

Q37933439-11F91071-90F8-4EAA-93AF-1056C8985E48

Q37933439-1254C2B1-EA9B-4933-9F73-FB7B04386E5E

Q37933439-1E13A06C-636B-4F68-918D-C2E34E0B2507

P304

Q37933439-DDED2206-1747-4120-937E-BF0B3D92EF01

P31

Q37933439-2AD3987F-E879-4125-95D9-1FDC205164BB

Q37933439-7C32EE6F-CC5B-4088-982A-AA6C3C51CC5B

P356

Q37933439-5020D2CB-92BC-455A-A719-196310FECE37

P433

Q37933439-0DA6E509-6C23-4F7F-81B9-734D08E69F27

P478

Q37933439-73CFDA33-08AA-4892-8305-70FD25CE4DA4

P577

Q37933439-41D687DC-53FE-4DEE-B49F-D11FA4AB8C66

Q37933439-CB39AC66-89A2-4DBA-B325-55404E3DA065

P5875

Q37933439-701EC849-7D7E-4E49-9A23-7E9D6EC294E8

P698

Q37933439-A1CD6CAD-5923-4D43-818E-738E9F064FEC

P921

Q37933439-1F8FD1EA-40F6-40FE-9E1F-6CE2477C11CD

Q37933439-88E9D31F-0240-4DFB-A873-0555B77B613D

P932

Q37933439-D8BE3A8C-597B-4D44-BC94-D5694E308EBD

P356

J.1751-7915.2011.00296.X

P1433

Microbial Biotechnology

P1476

Replicating viral vectors for ...... ze with host immune responses.

@en

P2093

Jennifer Altomonte

http://www.w3.org/2001/XMLSchema#string

Oliver Ebert

http://www.w3.org/2001/XMLSchema#string

P2860

Potentiating cancer immunotherapy using an oncolytic virus

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

Viral mimicry of cytokines, chemokines and their receptors

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

Tolerance, danger, and the extended family

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

P304

251-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1751-7915.2011.00296.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51648114

http://www.w3.org/2001/XMLSchema#string

P698

21923638

http://www.w3.org/2001/XMLSchema#string

P921

P932

3815785

http://www.w3.org/2001/XMLSchema#string